Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up

Introduction: Chemo-potentiation of radiation improves survival in women with cervical cancer. Our group has previously demonstrated the tolerability of weekly paclitaxel combined with cisplatin during radiation therapy. We sought to determine the efficacy of this regimen in patients with "high risk" cervical cancer, and to determine the short- and long-term toxicity of this approach.

Methods: We prospectively enrolled surgically staged patients with positive peritoneal cytology, resectable nodal metastases, or primary tumor > 6 cm. Patients were treated using external beam radiation with concomitant cisplatin (50 mg/m2) during weeks 1, 4, and 7, and weekly paclitaxel (50 mg/m2), followed by four courses of adjuvant cisplatin (50 mg/m2) and paclitaxel (135 mg/m2). Toxicity, overall, and disease-free survival were evaluated.

Results: Twenty-three patients were enrolled, and 21 were evaluable. Patient allotment by FIGO stage was: IB1 - seven, IB2 - five, IIA - two, IIB - four, IIIB - two, IV - three. Twenty patients (95%) completed radiation treatment (median dose to point A was 8278 cGy). Seventeen patients (81%) completed all chemotherapy. At a median follow-up of 58 months the overall survival was 68%. Overall survival for patients with clinical Stage I and II disease was 82% at a median of 64 months. Hematologic toxicity was common but rarely resulted in treatment delays. Late complications requiring intervention (obstruction, fistula, significant lymphocyst) occurred in 11 patients (52%).

Conclusion: The combination of paclitaxel and cisplatin appears efficacious in "high-risk" cervical cancer patients. Hematologic toxicity was common but tolerable. Long-term survival was common in these patients, however late toxicity was significant. This regimen should be investigated in collaborative phase III trials.

[1] Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: "Cancer Statistics, 2004". CA Cancer J. Clin., 2004, 54, 2.

[2] Hreshchyshyn M.M., Aron B.S., Boronow R.C., Franklin E.W 3'', Shingleton H.M., Blessing J.A.: "Hydroxyurea or placebocombined with radiation to treat Stages IIIB and IV cervical cancer confined to the pelvis". Int. J. Radial. Oncol. Biol. Phys., 1979, 5, 317.

[3] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. et al.: "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy of bulky Stage IB cervical carcinoma". N. Engl. J. Med., 1999, 340, 1154.

[4] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hanmgan E.V., Fowler W.C. et al.: "Randomized comparison of fluorouracil plu: cisplatin-versus hydroxyu:ea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study". J. Clin. Oncol., 1999, 17, 1339.

[5] Morris Mitchell M.,E ifel P.J.,L u J.,G rigsby P.W.,L evenback C., Stevens R.E. et al.: "Pelvic radiation with concurrent chernotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.

[6] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A. et al.: "Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer". N. Engl. J Med., 1999, 340, 1144.

[7] Peters W.A. 3'', Liu P.Y.. Barrett R.J. 2"'. Stock R.J., Monk B.J., Berek J.S. et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oncol., 2000, 18, 1606.

[8] Radovitch E., Fyles A.W., Pintilie M., Leung P.M.: "Role of mitornycin C in the development of late bowel toxicity following chernoradiation for locally advanced carcinoma of the cervix". Int. J. Radiat. Oncol. Biol. Phys., 1997, 38, 979.

[9] Grigsby P.W., Heydon K., Mutch D.G., Kirn R.Y., Eifel P.: "Longterm follow-up of RTOG 92-10: cervical cancer with positive paraaortic lymph nodes". Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 982.

[10] Berclaz G., Gerber E., Beer K., Aebi S., Greiner R., Dreher E., Buser K.: "Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochernotherapy". Int. J. Oncol., 2002, 20, 1313.

[11] Grigsby P.W.: "Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy". Int. J. Gynecol. Cancer, 2004, 14, 860.

[12] Chen M.D., Paley P.J., Potish R.A., Twiggs L.B.: "Phase I trial of paclitaxel as a radiation sensitizer with cisplatin in advanced cervical cancer". Gynecol. Oncol., 1997, 67, 131.

[13] Park T.K.: "Adjuvant therapy in cervical cancer patients with high risk factors". Yonsei Med. J., I 997, 38, 255.

[14] Monk B.J., Wang J., Im S., Stock R.J., Peters W.A. 3rd, Liu P.Y. et al.: "Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial". Gynecol. Oncol., 2005, 96, 721.

[15] McGuire W.P., Blessing J.A., Moore D., Lentz S.S., Photopulos G.: "Paclitaxel has moderate activity in squamous cervical cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 1996, 14, 792.

[16] Liebmann J., Cook J.A., Fisher J., Teague D., Mitchell J.B.: "In vitro studies of paclitaxel as a radiation sensitizer in human tumor cells". J. Natl. Cancer Inst., 1994, 86, 441.

[17] Tishler R.B., Geard C.R., Hall E.J., Schiff P.B.: "Paclitaxel sensitizes human astrocytoma cells to radiation". Cancer Res., 1992, 52, 3495.

[18] Steren A., Sevin B.U., Perras J., Angioli R., Nguyen H., Guerra L. et al.: "Paclitaxel sensitizes human ovarian cancer cells to radiation". Gynecol. Oncol., 1993, 48, 252.

[19] Jaakkola M., Rantanen V., Grenman S., Kulmala J., Grenman R.: "In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma lines". Cancer, 1996, 77, 1940.

[20] Rodriguez M., Sevin B.U., Perras J., Nguyen H.N., Pham C., Steren A.J. et al.: "Paclitaxel: a radiation sensitizer of human cervical cancer cells". Gynecol. Oncol., 1995, 57, 165.

[21] Geard C.R., Jones J.M.: "Radiaiton and Paclitaxel effects on synchronized human cancer cells". Int. J. Radial. Biol. Phys., 1994, 29, 565.

[22] Erlich E., McCall A.R., Potkul R.K., Walter S., Vaughan A.: "Paclitaxel is only a weak radiosensitizer of human cervical cancer cell lines". Gynecol. Oncol., 1996, 60, 251.

[23] Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J. et al.: "Phase III study of cisplatin with or without pac!itaxel in Stage IV B, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study". J. Clin. Oneal., 2004, 22, 3113.

[24] Goff B.A., Muntz H.G., PAley P.J., Tamimi H.K., Koh W.J., Greeer B.E.: "Impact of surgical staging in women with locally advanced cervical cancer". Gynecol. Oneal., 1999, 74, 436.

[25] Hasenburg A., Salama J.K., Van T.J., Amosson C., Chiu J.K., Kieback D.G.: "Evaluation of patients after exptraperitoneal lymph node dissection and subsequent radiation". Gynecol. Oneal., 2002, 84, 321.

[26] Cosin J.A., Fowler J.M., Chen M.D., Paley P.J., Carson L.F., Twiggs L.B.: "Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking". Cancer, 1998, 82, 2241.

[27] Zorlu C.G., Aydogdu T., Ergun Y., Kuscu E., Cobanoglu O., Kocak S.: "Complications of radical hysterectomy: Clinical experience of 115 early stage cervical cancers". Gynecol. Obstet. Invest., 1998, 45, 137.

[28] Uno T., Ito H., Itami J., Yasuda S., Isobe K., Hara R. et al.: "Postoperative radiation therapy for Stage IB-IIB carcinoma of the cervix with poor prognostic factors". Anticancer Res., 2000, 20, 2235.